| Literature DB >> 34641833 |
Yoshitaka Sekine1, Kazuhiko Kotani2, Daisuke Oka3, Hiroshi Nakayama3, Yoshiyuki Miyazawa3, Takahiro Syuto3, Seiji Arai3, Masashi Nomura3, Hidekazu Koike3, Hiroshi Matsui3, Yasuhiro Shibata3, Masami Murakami4, Kazuhiro Suzuki3.
Abstract
BACKGROUND: Recently, presepsin has been reported to be a useful biomarker for early diagnosis of sepsis and evaluation of prognosis in septic patients. However, few reports have evaluated its usefulness in patients with urinary tract infections (UTI). This study aimed to evaluate whether presepsin could be a valuable marker for detecting severe sepsis, and whether it could predict the therapeutic course in patients with UTI compared with markers already used: procalcitonin (PCT) and C-reactive protein (CRP).Entities:
Keywords: Bacterial infections; Biomarkers; C-reactive protein; Cytokines; Endotoxins; Flank pain; Presepsin; Sepsis; procalcitonin; Urinary tract infection
Mesh:
Substances:
Year: 2021 PMID: 34641833 PMCID: PMC8513358 DOI: 10.1186/s12894-021-00906-4
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Characteristics of Patients with or without septic shock on the enrollment day
| Variable | Total | Septic shock group | Non-septic shock group | |
|---|---|---|---|---|
| N = 50 | N = 11 | N = 39 | ||
| Age (years) | 66.5 [60.3–75.5]] | 64 [49–70] | 68 [61–78] | 0.055 |
| White blood cell (/mm3) | 13,600 [10,375–18,000] | 13,600 [9900–25600] | 13,600 [10400–16600] | 0.788 |
| C-reactive protein (mg/L) | 10.45 [4.26–23.06] | 11.47 [6.41–25.63] | 10.2 [4.21–22.37] | 0.406 |
| Presepsin (pg/mL) | 483 [277–1130] | 1380 [924–5219] | 399 [254–707] | < 0.001 |
| Procalcitonin (ng/mL) | 0.87 [0.20–17.1] | 25.06 [0.42–103.73] | 0.66 [0.14–2.06] | 0.056 |
| Aspartate transaminase (U/L) | 24.5 [19.8–35.3] | 44 [24–133] | 24 [18–29] | 0.003 |
| Alanine transaminase (U/L) | 17 [11.8–30.0] | 19 [15–52] | 17 [11–24] | 0.049 |
| γ-glutamyl transpeptidase (U/L) | 31 [21.0–53.3] | 70 [43–74] | 26 [20–43] | 0.002 |
| Creatinine (mg/dL) | 1.24 [0.87–1.99] | 1.85 [1.19–3.86] | 1.05 [0.85–1.84] | 0.020 |
| sex (male/female) | 33/17 | 8/3 | 25/14 | 0.440 |
| placement of urinary catheter (Y/N) | 24/26 | 6/5 | 18/21 | 0.623 |
| urological cancer (Y/N) | 15/35 | 1/10 | 14/25 | 0.085 |
| urinary calculi (Y/N) | 12/38 | 4/7 | 8/31 | 0.240 |
| DM (Y/N) | 9/41 | 3/8 | 6/33 | 0.308 |
| internal use of steroid (Y/N) | 9/41 | 3/8 | 6/33 | 0.308 |
Values are expressed as number or median [interquartile range, IQR]
DM diabetes mellitus, Y yes, N No
Prediction of septic shock on the enrollment day by logistic regression analysis
| Variable | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Sex (male vs female) | 0.595 | |||||
| WBC (4000–12,000 vs other) | 0.497 | |||||
| CRP (≥ 0.5 vs < 0.5) | 0.360 | |||||
| CRP (≥ 10 vs < 10) | 0.848 | |||||
| Presepsin (≥ 500 vs < 500) | 0.007 | 20.000 | 2.305–173.553 | 0.029 | 12.157 | 1.298–113.892 |
| PCT (≥ 0.05 vs < 0.05) | 0.630 | |||||
| PCT (≥ 2 vs < 2) | 0.025 | 5.075 | 1.223–21.065 | 0.673 | ||
| AST (≥ 34 vs < 34) | 0.006 | 8.000 | 1.829–34.996 | 0.375 | ||
| ALT (≥ 28 vs < 28) | 0.105 | |||||
| γGPT (≥ 47 vs < 47) | 0.005 | 8.889 | 1.941–40.711 | 0.081 | ||
| Cr (male; ≥ 1.07 vs < 1.07, female; ≥ 0.79 vs < 0.79) | 0.095 | |||||
| placement of urinary catheter (Y vs N) | 0.624 | |||||
| urological cancer (Y vs N) | 0.118 | |||||
| urinary calculi (Y vs N) | 0.284 | |||||
| DM (Y vs N) | 0.371 | |||||
| internal use of steroid (Y vs N) | 0.371 | |||||
WBC white blood cell, CRP C-reactive protein, PCT procalcitonin, AST aspartate transaminase, ALT Alanine transaminase, γGTP γ-glutamyl transpeptidase, Cr creatinine, DM diabetes mellitus, Y yes, N no
Fig. 1ROC curve for presepsin, procalcitonin, CRP, and WBC in patients with definitive diagnosis of septic shock on the enrollment day and SIRS on the 5th day after admission. Abbreviations: P-SEP; presepsin, PCT; procalcitonin, CRP; C-reactive protein, WBC; white blood cell
Characteristics of Patients with or without SIRS on the 5th day
| Variable | SIRS group | Non-SIRS group | |
|---|---|---|---|
| N = 7 | N = 43 | ||
| Age (years) | 64 [54–68] | 68 [61–77] | 0.126 |
| Day1/White blood cell (/mm3) | 18,200 [17,200–24900] | 13,600 [9900–16,000] | 0.009 |
| Day1/C-reactive protein (mg/L) | 25.63 [9.58–31.38] | 8.23 [4.1–16.6] | 0.007 |
| Day1/Presepsin (pg/mL) | 1167 [878–5129] | 419 [277–922] | 0.006 |
| Day1/Procalcitonin (ng/mL) | 73.1 [25.06–103.73] | 0.55 [0.14–2.06] | 0.003 |
| Day1/Aspartate transaminase (U/L) | 34 [28–126] | 24 [18–33] | 0.013 |
| Day1/Alanine transaminase (U/L) | 23 [18–52] | 16 [11–25] | 0.056 |
| Day1/γ-glutamyl transpeptidase (U/L) | 48 [38–72] | 28 [21–51] | 0.133 |
| Day1/Creatinine (mg/dL) | 2.30 [1.72–2.71] | 1.05 [0.85–1.84] | 0.007 |
| Day3/White blood cell (/mm3) | 11,900 [9400–20,100] | 8400 [5900–10,400] | 0.021 |
| Day3/C-reactive protein (mg/L) | 25.58 [16.47–34.54] | 10.71 [6.55–15.40] | < 0.001 |
| Day3/Presepsin (pg/mL) | 633 [464–1360] | 311 [196–695] | 0.027 |
| Day3/Procalcitonin (ng/mL) | 20.34 [14.23–32.27] | 1.35 [0.30–15.09] | 0.005 |
| Sex (male/female) | 4/3 | 29/14 | 0.446 |
| Urinary culture (P/N) | 7/0 | 38/5 | 0.454 |
| Blood culture (P/N) | 6/1 | 18/25 | 0.039 |
| Placement of urinary catheter (Y/N) | 2/5 | 22/21 | 0.244 |
| Urological cancer (Y/N) | 1/6 | 14/29 | 0.311 |
| Urinary calculi (Y/N) | 4/3 | 8/35 | 0.048 |
| DM (Y/N) | 1/6 | 8/35 | 0.630 |
| Surgical procedure (Y/N) | 6/1 | 22/21 | 0.095 |
| Internal use of steroid (Y/N) | 2/5 | 7/36 | 0.370 |
Values are expressed as number or median [interquartile range, IQR]
DM diabetes mellitus, P positive, N no, Y yes
Prediction of SIRS on the 5th day by logistic regression analysis
| Variable | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Day1/WBC (4000–12,000 or other) | 0.19 | |||||
| Day1/CRP (≥ 10 or < 10) | 0.280 | |||||
| Day1/Presepsin (≥ 500 or < 500) | 0.049 | 9.176 | 1.013–83.108 | 0.366 | ||
| Day1/PCT (≥ 2 or < 2) | 0.012 | 17.455 | 1.886–161.528 | 0.012 | 17.455 | 1.886–161.528 |
| Day1/AST (≥ 34 or < 34) | 0.079 | |||||
| Day1/ALT (≥ 28 or < 28) | 0.283 | |||||
| Day1/γGPT (≥ 47 or < 47) | 0.177 | |||||
| Day1/Cr (male; ≥ 1.07 or < 1.07, female; ≥ 0.79 or < 0.79) | 0.998 | |||||
Day3/WBC (4000–12,000 or other) | 0.120 | |||||
| Day3/CRP (≥ 10 or < 10) | 0.998 | |||||
| Day3/Presepsin (≥ 500 or < 500) | 0.067 | |||||
| Day3/PCT (≥ 2 or < 2) | 0.998 | |||||
| Sex (male or female) | 0.596 | |||||
| Urinary culture (P vs N) | 0.999 | |||||
| Blood culture (P vs N) | 0.059 | |||||
Placement of urinary catheter (Y vs N) | 0.280 | |||||
| Urological cancer (Y vs N) | 0.346 | |||||
| Urinary calculi (Y vs N) | 0.040 | 5.833 | 1.084–31.377 | 0.182 | ||
| DM (Y vs N) | 0.783 | |||||
| Surgical procedure (Y vs N) | 0.120 | |||||
| Internal use of steroid (Y vs N) | 0.439 | |||||
WBC white blood cell, CRP C-reactive protein, PCT procalcitonin, AST aspartate transaminase, ALT alanine transaminase, γGTP γ-glutamyl transpeptidase, Cr creatinine, DM diabetes mellitus, P positive, N no, Y yes